Bullish & Foolish
Full SPRB fundamentals All 466 on the Survival Watch

SPRBSpruce Biosciences, Inc.

Is Spruce Biosciences struggling financially?

Yes, by its own account. Spruce Biosciences told the SEC on 9 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Cries for help

  • Share sales and shelf filings

    In November 2025, the U.S. Securities and Exchange Commission (“SEC”) declared effective a registration statement on Form S-3 (the “Shelf Registration”), covering the sale of up to $ 300.0 million of the Company's securities.

    Form 10-Q, filed 13 May 2026. Read it on SEC.gov

  • Reverse stock split

    Subsequently on August 4, 2025, the Company effected a one-for-seventy-five (1:75) reverse stock split of its outstanding common stock (the “Reverse Stock Split”).

    Form 10-Q, filed 13 May 2026. Read it on SEC.gov

  • Long-term agreements

    In particular, we currently rely on a single-source manufacturer for drug product, and a single-source manufacturer for drug substance. We currently have a long-term agreement with a manufacturer to produce raw materials, active pharmaceutical ingredients (“APIs”), and the finished product of TA-ERT.

    Form 10-Q, filed 13 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$148.2M
Source filing
10-K 9 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

  • 13months

    If the burn speeds up

    Empty by Jul 2027

  • 19months

    If it eases off

    Empty by Jan 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$96.3M

÷

Cash burned over the last 12 months

$73.1M

What Spruce Biosciences told the SEC

…with our business include the following: We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern. We will need substantial additional financing to develop our product candidates and implement our operating plan. If we fail to obtain additional financing, including as a result of…

Spruce Biosciences, Inc., Form 10-K, filed 9 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 223.5% share-count increase The company issued stock. Each share now owns 69.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt